The mutant Nf1 fly provided some of the first evidence that dysregulation of Ras pathway signaling is a major cause of Neurofibromatosis 1 (Williams et al., 2001), and this result was further supported by Barkan et al. (2006), who in 2006 demonstrated the use of a Ras inhibitor as a potential drug for the treatment of NF1. This evidence concerns the gene NF1 and neurofibromatosis type 1.